Five Cases of Bisphosphonate Therapy on Children with McCune-Albright Syndrome and Literature Review
TANG Yan1, CHANG Miao-miao2, DU Bo-ran3, ZHU Hui-juan4*, MEI Dan1, FENG Kai4, YANG Hong-bo4, WANG Ou4, XING Xiao-ping4
1. Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; 2. Department of Pharmacy, 309 Hospital of PLA, Beijing 100091, China; 3. Beijing Obstetrics and Gynecology Hospital,Capital Medical University,Beijing 100026,China; 4. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
Abstract��OBJECTIVE To provide references for clinical rational drug use through five empirical analysis of zoledronate��s application on children with McCune-Albright syndrome.METHODS The clinical data of five children with McCune-Albright syndrome were analyzed and summarized. Literature review was conducted to analyze long-term out come of bisphosphonate therapy and factors influencing outcome of bisphosphonate therapy in fibrous dysplasia. RESULTS Bisphosphonate therapy achieved certain effects, and there were no serious adverse events occurred. CONCLUSION Bisphosphonate therapy can be used on children with McCune-Albright syndrome,the prognostic factor that influencing outcome of bisphosphonate therapy is the extent of skeletal involvement.
����, ������, �Ų�Ƚ, ��ݾ�, ÷��, �뿭, ���鲨, ��Ÿ, ��Сƽ. ˫����������ƶ�ͯMcCune-Albright�ۺ�����Ӧ��[J]. �й�ҩѧ��־, 2019, 54(2): 132-136.
TANG Yan, CHANG Miao-miao, DU Bo-ran, ZHU Hui-juan, MEI Dan, FENG Kai, YANG Hong-bo, WANG Ou, XING Xiao-ping. Five Cases of Bisphosphonate Therapy on Children with McCune-Albright Syndrome and Literature Review. Chinese Pharmaceutical Journal, 2019, 54(2): 132-136.
ALBRIGHT F, BUTLER A M, HAMPTON A O, et al. Syndrome characterized by osteitis fibrosa disseminata, areas, of pigmentation, and endocrine dysfunction, with precocious puberty in females[J]. N Engl J Med, 1937, 216:727-746.
[2]
LALA R, MATARAZZO P, ANDREO M. Bisphosphonate treatment of bone fibrous dysplasiain McCune-Albright syndrome[J]. J Pediatr Endocrinol Metab, 2006,19(suppl 2):583-593.
[3]
TESSARIS D, MATARAZZO P, LALA R, et al. Odontoiatric perspectives and osteonecrosis of the jaw as a possible adverse effect of bisphosphonates therapy in fibrous dysplasia and McCune-Albright syndrome[J]. J Pediatr Endocrinol Metab, 2016, 29(3):333-336.
[4]
WANG W B, WANG O, Pathogenesis and pharmacological treatment of fibrous dysplasia[J]. Chin J Osteoprosis Bone Miner Res(�л��������ɺǿ��μ�����־),2014,12(4):350-356.
[5]
NGAN K K, BOWE J, GOODGER N. The risk of bisphosphonate-related osteonecrosis of the jaw in children. A case report and literature review[J]. Dent Update,2013,40(9):733-734,736-738.
[6]
PAPAPETROU P D. Bisphosphonate-associated adverse events[J]. Hormones,2009,8(2):96-110.
[7]
GEORGE S, WEBER D R, KAPLAN P, et al. Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience[J]. J Clin Endocrinol Metab, 2015,100(11):4163-4171.
[8]
KUMAR C, PANIGRAHI I, SOMASEKHARAARADHYA A, et al. Zoledronate for osteogenesis imperfecta: evaluation of safety profile in children[J]. J Pediatr Endocrinol Metab,2016,29(8):947-952.
[9]
MAJOOR B C, APPELMAN-DIJKSTRAN M, FIOCCO M, et al. Outcome of long-term bisphosphonate therapy in McCune-Albright syndrome and polyostotic fibrous dysplasia[J]. J Bone Miner Res,2017,32(2):264-276.
[10]
BROWN J, RAMALINGAM L, ZACHARIN M. Bisphosphonate-associated osteonecrosis of the jaw:does it occur in children? [J]. Clin Endocrinol, 2008,68(6):863-867.
[11]
CHAPURLAT R D, HUGUENY P, DELMAS P D, et al. Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment[J]. Bone,2004,35(1):235-242.
[12]
CHAN B, ZACHARIN M. Pamidronate treatment of polyostotic fibrous dysplasia: failure to prevent expansion of dysplastic lesions during childhood[J]. J Pediatr Endocrinol Metab,2006,19(1):75-80.
[13]
KOS M, LUCZAK K, GODZINSKI J, et al. Treatment of monostotic fibrous dysplasia with pamidronate[J]. J Cranio-Maxillofac Surg,2004,32:10-15.
[14]
PLOTKIN H, RAUCH, FZEITLIN L, et al. Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone[J]. J Clin Endocrinol Metab,2003,88(16):4569-4575.
[15]
AYCAN Z, ÖNDER A, ÇETINKAYA S. Eight-year follow-up of a girl with McCune-Albright syndrome[J]. J Clin Res Pediatr Endocrinol,2011,3(1):40-42.
[16]
ARAGÃO A L, SILVA I N. Oral alendronate treatment for severe polyostotic fibrous dysplasia due to McCune-Albright syndrome in a child: a case report[J]. Int J Pediatr Endocrinol,2010:432060.
[17]
BOYCE A M, KELLY M H, BRILLANTE B A, et al. A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone[J]. J Clin Endocrinol Metabol,2014,99(11):4133-4140.
[18]
COLLINS M T, KUSHNER H, REYNOLDS J C, et al. An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone[J]. J Bone Miner Res,2005,20(2):219-226.
2019, Vol. 54 
